Reported 8 months ago
After the shareholders' meeting on June 17, 2024, at 4:10 PM, Haodin's CEO, Wang Huijun, announced the focus on advancing a new drug into clinical trials annually through patented dual-function enzymes and glycosylation platforms. ADC will be the main business development focus, with OBI-992 expected to enter phase II clinical trials next year and actively seeking licensing opportunities. The company plans to conduct a capital increase in the second half of the year to raise necessary funds for the next one to two years. Additionally, the highly anticipated new treatment for triple-negative breast cancer, OBI-822/OBI-821, is poised for a second mid-term analysis by the end of the year and unblinding in early 2026. Haodin has revealed five major operational goals for the year, emphasizing clinical trial progress, international collaborations, and innovative drug development.
Source: YAHOO